Immunoglobulin Therapy of Sepsis

D.V. Maltsev

Abstract


Approbation of immunoglobulin therapy in sepsis was based on the concept of antimicrobial, antiinflammatory and immunomodulatory effects of antibodies. Immunoglobulin preparations are being used in septic pathology at least in two ways — directly for sepsis management and suppression of manifestations of systemic inflammatory response and to prevent this complication in specific high-risk groups, such as premature infants with hypoimmunoglobulinemia. Currently, three kinds of immunoglobulin preparations were tested: multivalent immunoglobulin, containing almost exclusively IgG, immunoglobulin enriched with IgM and IgA, and monoclonal specific immunoglobulins, particularly antibodies to endotoxin. Most evidence base is accumulated for IgG-containing polyvalent immunoglobulin, however, it seems that each of the formulations has advantages in certain subgroups of patients.
The availability in Ukraine of monocomponent multivalent IgG-containing intravenous immunoglobulin Octagam produced by Swiss company Octapharma lets be optimistic about the therapy of patients in need of this type of treatment. Octagam distinguishes good tolerability proved in the 11-year prospective observational study [101], a high degree of viral safety [101] and comfortable conditions of storage (from +2 to +25 °C) [102]. In addition, the maximum rate of Octagam administration is 0.08 ml/kg/min [102], which makes the drug irreplaceable in situations when rapid initiation of therapy is need.
At the moment, immunoglobulin is positioned as a second-line agent for the treatment of sepsis in unfavourable course of the pathological process, high risk of death and multiresistance of microorganism to antimicrobial chemotherapy. However, immunoglobulin still has vast therapeutic niches in septic patients. We are talking about the separate subgroups of patients, in whom it is appropriate to use immunoglobulin as a first-line drug for bacterial sepsis along with antibiotic therapy. This are the persons with streptococcal necrotizing fasciitis and toxic shock, pregnant women, children infected with HIV, patients with toxic epidermal necrolysis or autoimmune complications, in which the efficacy of immunoglobulin therapy was proved, as well as immunocompromised patients with primary and secondary hypo- or disimmunoglobulinemia.


Keywords


sepsis; immunoglobulin; immunotherapy; Octagam

References


Aakalu V.K., Sajja K., Cook J.L., Ahmad A.Z. Group A streptococcal necrotizing fasciitis of the eyelids and face managed with debridement and adjunctive intravenous immunoglobulin // Ophthal. Plast. Reconstr. Surg. 2009 Jul-Aug; 25(4): 332-4.

Abinun M., Cant A.J. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome // Lancet. 1994 Jan 29; 343(8892): 300.

Akdag A., Dilmen U., Haque K. et al. Role of Pentoxifylline and/or IgM-Enriched Intravenous Immunoglobulin in the Management of Neonatal Sepsis // Am. J. Perinatol. 2014 Feb 10. [Epub ahead of print].

Alejandria M.M., Lansang M.A., Dans L.F., Mantaring J.B. 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock // Cochrane Database Syst. Rev. 2013 Sep 16; 9: CD001090.

Alejandria M.M., Lansang M.A., Dans L.F., Mantaring J.B. Intravenous immunoglobulin for treating sepsis and septic shock // Cochrane Database Syst. Rev. 2002; (1): CD001090.

Alejandria M.M., Lansang M.A., Dans L.F., Mantaring J.B. Intravenous immunoglobulin for treating sepsis and septic shock // Cochrane Database Syst. Rev. 2000; (2): CD001090.

Almeida J.F., Sztajnbok J., Troster E.J., Vaz F.A. Pseudomonas aeruginosa septic shock associated with ecthyma gangrenosum in an infant with agammaglobulinemia // Rev. Inst. Med. Trop. Sao Paulo. 2002 May-Jun; 44(3): 167-9.

Al-Rawi S., Woodward L.J., Knight J. et al. Puerperal streptococcal toxic shock syndrome treated with recombinant human activated protein C and intravenous immunoglobulin // Int. J. Obstet. Anesth. 2009 Apr; 18(2): 169-72.

Arnholm B., Lundqvist A., Strimberg A. High-dose immunoglobulin — life-saving in invasive group A streptococcal infection. Report of eleven cases with only one fatality // Lakartidningen. 2004 Aug 26; 101(35): 2642-4.

Basile N., Danielian S., Oleastro M. et al. Clinical and molecular analysis of 49 patients with X-linked agammaglobulinemia from a single center in Argentina // J. Clin. Immunol. 2009 Jan; 29(1): 123-9.

Berlot G., Vassallo M.C., Busetto N. et al. Relationship between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis // J. Crit. Care. 2012 Apr; 27(2): 167-71.

Bloom B., Schelonka R., Kueser T. et al. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcalimmunoglobulin, for prevention of nosocomial infections in very low birth weight infants // Pediatr. Infect. Dis. J. 2005 Oct; 24(10): 858-66.

Bradley T.M., Smoot E.C. 3rd, Graham D.R. et al. Overwhelming postsplenectomy sepsis in a patient with burns: a case report and a rational approach to treatment // J. Burn. Care Rehabil. 1995 Sep-Oct; 16(5): 525-30.

Brunner R., Rinner W., Haberler C. et al. Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial // Crit. Care. 2013 Oct 2; 17(5): R213.

Buda S., Riefolo A., Biscione R. et al. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery // J. Cardiothorac. Vasc. Anesth. 2005 Aug; 19(4): 440-5.

Bussel J.B. Intravenous gammaglobulin in the prophylaxis of late sepsis in very-low-birth-weight infants: preliminary results of a randomized, double-blind, placebo-controlled trial // Rev. Infect. Dis. 1990 May-Jun; 12 Suppl 4: S457-61.

Cafiero F., Gipponi M., Bonalumi U. et al. Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsisundergoing surgery for colorectal cancer: results of a randomized, multicenter clinical trial // Surgery. 1992 Jul; 112(1): 24-31.

Cairo M.S., Worcester C.C., Rucker R.W. et al. Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy for neonatal neutropenia and sepsis // J. Pediatr. 1992 Feb; 120(2 Pt 1): 281-5.

Cawley M.J., Briggs M., Haith L.R. Jr. et al. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review // Pharmacotherapy. 1999 Sep; 19(9): 1094-8.

Chapel H.M., Lee M., Hargreaves R. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma // Lancet. 1994 Apr 30; 343(8905): 1059-63.

Chiu C.H., Ou J.T., Chang K.S., Lin T.Y. Successful treatment of severe streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone and antibiotics // Infection. 1997 Jan-Feb; 25(1): 47-8.

Cone L.A., Stone R.A., Schlievert P.M. et al. An early favorable outcome of streptococcal toxic shock syndrome may require a combination of antimicrobial and intravenous gamma globulin therapy together with activated protein C // Scand. J. Infect. Dis. 2006; 38(11-12): 960-3.

Darenberg J., Ihendyane N., Sjölin J., Aufwerber E., Haidl S., Follin P. et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomised, double-blind, placebo-controlled trial // Clin. Infect. Dis. 2003; 37: 333-40.

Darenberg J., Söderquist B., Normark B.H., Norrby-Teglund A. Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome // Clin. Infect. Dis. 2004 Mar 15; 38(6): 836-42.

Davidson R.N., Wall R.A. Prevention and management of infections in patients without a spleen // Clin. Microbiol. Infect. 2001 Dec; 7(12): 657-60.

de Weerd A., Vonk A., van der Hoek H. et al. Late antibody-mediated rejection after ABO-incompatible kidney transplantation during Gram-negative sepsis // BMC Nephrol. 2014 Feb 12; 15(1): 31.

Deleu D., Salim K., Mesraoua B. et al. Man-in-the-barrel syndrome as delayed manifestation of extrapontine and central pontine myelinolysis: beneficial effect of intravenous immunoglobulin // J. Neurol. Sci. 2005 Oct 15; 237(1-2): 103-6.

Dominioni L., Dionigi R., Zanello M. et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater // Arch. Surg. 1991 Feb; 126(2): 236-40.

Douzinas E.E., Pitaridis M.T., Louris G., Andrianakis I., Katsouyanni K., Karmpaliotis D., Economidou J., Syfras D., Roussos C. Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins // Crit. Care Med. 2000 Jan; 28(1): 8-15.

El-Nawawy A., El-Kinany H., Hamdy El-Sayed M., Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit // J. Trop. Pediatr. 2005 Oct; 51(5): 271-8.

Feigenberg T., Sela H.Y., Applbaum Y.H., Mankuta D. Puerperal widespread pyomyositis after group A streptococcal toxic shock syndrome // Isr. Med. Assoc. J. 2008 Jun; 10(6): 483-4.

Frame J.D., Everitt A.S., Gordon P.W., Hackett M.E. IgG subclass response to gamma globulin administration in burned children // Burns. 1990 Dec; 16(6): 437-40.

Franco A.C., Torrico A.C., Moreira F.T. Adjuvant use of intravenous immunoglobulin in the treatment of neonatal sepsis: a systematic review with a meta-analysis // J. Pediatr. (Rio J). 2012 Sep-Oct; 88(5): 377-83.

Friedman C.A., Robbins K.K., Temple D.M. et al. Survival and neutrophil kinetics in infants with severe group B streptococcal disease treated with gamma globulin // J. Perinatol. 1996 Nov-Dec; 16(6): 439-42.

Galal N.M. Pattern of intravenous immunoglobulins (IVIG) use in a pediatric intensive care facility in a resource limited setting // Afr. Health Sci. 2013 Jun; 13(2): 261-5.

Graffin B., Goutorbe P., Poyet R. et al. Multi-organ failures during septic shock from Escherichia coli urinary tract infection: catastrophic antiphospholipid syndrome? // Rev. Med. Interne. 2007 Jan; 28(1): 52-5.

Gupta M. et al. Cytokine modulation with immune γ-globulin in peripheral blood of normal children and its implications in Kawasaki disease treatment // J. Clin. Immunol. 2001; 21, 193-199.

Helmig R.B., Arpi M. Life-threatening puerperal sepsis caused by group A streptococci // Ugeskr. Laeger. 2000 May 15; 162(20): 2891-2.

Hsueh K.C., Chiu H.H., Lin H.C. et al. Transient hypogammaglobulinemia of infancy presenting as Staphylococcus aureus sepsis with deep neck infection // J. Microbiol. Immunol. Infect. 2005; 38(2): 141-144.

Izdes S., Altintas N.D., Eldem A. et al. Intravenous polyclonal IgM-enriched immunoglobulin therapy for resistant Acinetobacter sepsis in a pregnant patient with ARDS due to H1N1 infection // Int. J. Obstet. Anesth. 2011 Jan; 20(1): 99-100.

Jenson H.B., Pollock B.H. Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis // Pediatrics. 1997 Feb; 99(2): E2.

Kaul R., McGeer A., Norrby-Teglund A. et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome — a comparative observational study. The Canadian Streptococcal Study Group // Clin. Infect. Dis. 1999 Apr; 28(4): 800-7.

Kojima C., Yumura W., Itabashi M. et al. A case of microsco­pic polyangitis with sepsis due to pyelonephritis // Nihon Jinzo Gakkai Shi. 2005; 47(8): 876-81.

Korzets A., Ori Y., Zevin D. et al. Group A streptococcal bacteraemia and necrotizing faciitis in a renal transplant patient: a case for intravenous immunoglobulin therapy // Nephrol. Dial. Transplant. 2002 Jan; 17(1): 150-2.

Kreymann K.G., de Heer G., Nierhaus A., Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock // Crit. Care Med. 2007 Dec; 35(12): 2677-85.

Kyles D.M., Baltimore J. Adjunctive use of plasmapheresis and intravenous immunoglobulin therapy in sepsis: a case report // Am. J. Crit. Care. 2005 Mar; 14(2): 109-12.

Lamari F., Anastassiou E.D., Stamokosta E. et al. Determination of slime-producing S. epidermidis specific antibodies in human immunoglobulin preparations and blood sera by an enzyme immunoassay: correlation of antibody titers with opsonic activity and application to preterm neonates // J. Pharm. Biomed. Anal. 2000 Aug 15; 23(2-3): 363-74.

Laupland K. Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically ill adults // Can. J. Infect. Dis. 2002 Mar; 13(2): 100-6.

Laupland K.B., Kirkpatrick A.W., Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis // Crit. Care Med. 2007 Dec; 35(12): 2686-92.

Malik S., Giacoia G.P., West K. The use of intravenous immunoglobulin (IVIG) to prevent infections in bronchopulmonary dysplasia: report of a pilot study // J. Perinatol. 1991 Sep; 11(3): 239-44.

Maltbaek N., Harreby M.S., Thшgersen B. Intravenous immunoglobulin administration to a patient with systemic lupus erythematosus and pneumococcal septicemia // Ugeskr. Laeger. 1994 Jul 4; 156(27): 4039-41.

Mancilla-Ramírez .J, González-Yunes R., Castellanos-Cruz C. et al. Intravenous immunoglobulin in the treatment of neonatal septicemia // Bol. Med. Hosp. Infant. Mex. 1992 Jan; 49(1): 4-11.

Marenović T., Filipović D., Lukić Z., Dokić G. High doses of immunoglobulins decrease mortality rate of surgical patients with severe intraabdominal infections and sepsis // Vojnosanit Pregl. 1998 Mar-Apr; 55(2 Suppl): 71-4.

Martín-Nalda A, Soler-Palacín P, Español Borén T. et al. Spectrum of primary immunodeficiencies in a tertiary hospital over a period of 10 years // An. Pediatr. (Barc). 2011 Feb; 74(2): 74-83.

Mohr M., Englisch L., Roth A. et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis // Intensive Care Med. 1997 Nov; 23(11): 1144-9.

Murthy B.V., Nelson R.A., Mannion P.T. Immunoglobulin therapy in non-menstrual streptococcal toxic shock syndrome // Anaesth. Intensive Care. 2003 Jun; 31(3): 320-3.

Myrianthefs P.M., Boutzouka E., Baltopoulos G.J. Gamma-globulin levels in patients with community-acquired septic shock // Shock. 2010 May; 33(5): 556-7.

Neilson A.R., Burchardi H., Schneider H. Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsisand septic shock // J. Crit. Care. 2005 Sep; 20(3): 239-49.

Nettagul R., Visitsunthorn N., Vichyanond P. A case of IgG subclass deficiency with the initial presentation of transient hypogammaimmuno-globulinemia of infancy and a review of IgG subclass deficiencies // J. Med. Assoc. Thai. 2003 Jul; 86(7): 686-92.

Norrby-Teglund A., Haque K.N., Hammarström L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis // J. Intern. Med. 2006 Dec; 260(6): 509-16.

Norrby-Teglund A., Ihendyane N., Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections // Scand. J. Infect. Dis. 2003; 35(9): 683-9.

Norrby-Teglund A., Low D.E., McGeer A., Kotb M. Superantigenic activity produced by group A streptococcal isolates is neutralized by plasma from IVIG-treated streptococcal toxic shock syndrome patients // Adv. Exp. Med. Biol. 1997; 418: 563-6.

Norrby-Teglund A., Muller M.P., Mcgeer A. et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach // Scand. J. Infect. Dis. 2005; 37(3): 166-72.

Oba Y., Iwata K. Treatment of neonatal sepsis with immune globulin // N. Engl. J. Med. 2012 Jan 5; 366(1): 91.

Ogawa M., Ueda S., Anzai N. et al. Toxic shock syndrome after staphylococcal pneumonia treated with intravenous immunoglobulin // Vox. Sang. 1995; 68(1): 59-60.

Ohlsson A., Lacy J.B. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants // Cochrane Database Syst. Rev. 2000; (2): CD000361.

Ohlsson A., Lacy J.B. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants // Cochrane Database Syst. Rev. 2013 Jul 2; 7: CD000361.

Ohlsson A., Lacy J.B. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants// Cochrane Database Syst. Rev. 2004; (1): CD000361.

Olopoenia L., Young M., White D. et al. Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection // J. Natl. Med. Assoc. 1997 Aug; 89(8): 543-7.

Perez C.M., Kubak B.M., Cryer H.G. et al. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review // Am. J. Med. 1997 Jan; 102(1): 111-3.

Pilz G., Appel R., Kreuzer E., Werdan K. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis // Chest. 1997 Feb; 111(2): 419-26.

Pilz G., Kreuzer E., Kääb S. et al. Early immunoglobulin therapy in high risk patients for infection after heart surgery // Infusionsther Transfusionsmed. 1993 Apr; 20 Suppl. 1: 35-40.

Pilz G., Kreuzer E., Kääb S. et al. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients // Chest. 1994 Jan; 105(1): 76-82.

Plebani A., Soresina A., Rondelli R. et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study // Clin. Immunol. 2002 Sep; 104(3): 221-30.

Qu T., Feng Y., Jiang Y. et al. Whole genome analysis of a community-associated methicillin-resistant Staphylococcus aureus ST59 isolate from a case of human sepsis and severe pneumonia in China // PLoS One. 2014 Feb 20; 9(2): e89235.

Raithatha A.H., Bryden D.C. Use of intravenous immunoglobulin therapy in the treatment of septic shock, in particular severe invasive group A streptococcal disease // Indian J. Crit. Care Med. 2012 Jan; 16(1): 37-40.

Rajaratnam R., Mann C., Balasubramaniam P. et al. Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre // Clin. Exp. Dermatol. 2010 Dec; 35(8): 853-62.

Ratrisawadi V., Srisuwanporn T., Puapondh Y. Intravenous immunoglobulin prophylaxis for infection in very low birth-weight infants // J. Med. Assoc. Thai. 1991 Jan; 74(1): 14-8.

Ravetch J. In vivo veritas: the surprising roles of Fc receptors in immunity // Nat. Immunol. 2010, 11: 183-185.

Rehberg S., Freise H., Young P. et al. Sepsis-associated Guillain-Barrй syndrome // Anaesthesist. 2009 Feb; 58(2): 153-5.

Reith H.B., Rauchschwalbe S.K., Mittelkоtter U. et al. IgM-enriched immunoglobulin (pentaglobin) positively influences the course of post-surgical intra-abdominal infections // Eur. J. Med. Res. 2004 Oct 29; 9(10): 479-84.

Rodríguez A., Rello J., Neira J. et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery // Shock. 2005 Apr; 23(4): 298-304.

Romero-Legro I., Kadaria D., Murillo L.C., Freire A.X. Intravenous gammaglobulin as rescue therapy in a patient with sickle cell and septic shock // Tenn. Med. 2013 Oct; 106(9): 29-31.

Schaffer F.M., Newton J.A. Intravenous gamma globulin administration to common variable immunodeficient women during pregnancy: case report and review of the literature // J. Perinatol. 1994 Mar-Apr; 14(2): 114-7.

Schrage B., Duan G., Yang L.P., Fraser J.D., Proft T. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome // Clin. Infect. Dis. 2006 Sep 15; 43(6): 743-6.

Shankar-Hari M., Spencer J., Sewell W.A. et al. Bench-to-bedside review: Immunoglobulin therapy for sepsis — biological plausibility from a critical care perspective // Crit. Care. 2012 Dec 12; 16(2): 206.

Sifringer M., Spies C.D. The blood-brain barrier in sepsis: are intravenous immunoglobulins preventive? // Crit. Care Med. 2012 Apr; 40(4): 1368-9.

Soares M.O., Welton N.J., Harrison D.A. et al. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial ofintravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis // Health Technol. Assess. 2012; 16(7): 1-186.

Taccone F.S., Stordeur P., De Backer D. et al. Gamma-globulin levels in patients with community-acquired septic shock // Shock. 2009 Oct; 32(4): 379-85.

Tanzer F., Yazar N., Hakgüdener Y., Kafali G. Intravenous immunoglobulin for sepsis prevention in preterm infants // Turk. J. Pediatr. 1997 Jul-Sep; 39(3): 341-5.

Trent J., Halem M., French L.E., Kerdel F. Toxic epidermal necrolysis and intravenous immunoglobulin: a review // Semin. Cutan. Med. Surg. 2006 Jun; 25(2): 91-3.

Tuğrul S., Ozcan P.E., Akinci O. et al. The effect of pentaglobin therapy on prognosis in patients with severe sepsis // Ulus Travma Derg. 2001 Oct; 7(4): 219-23.

Van Den Bossche M.J., Devriendt D., Weyne L., Van Ranst M. Primary peritonitis combined with streptococcal toxic shock syndrome following an upper respiratory tract infection caused by Streptococcus pyogenes // Ned. Tijdschr. Geneeskd. 2008 Apr 12; 152(15): 891-4.

Vassilev T., Bauer M. Passive immunotherapy of sepsis with intravenous immune globulin: not all IVIg preparations are created equal // Crit. Care. 2012 Jan 25; 16(1): 407.

Vizquez Garcia R.E., Hernindez Bautista V., Espinosa Padilla S. Superantigens and toxic shock syndrome. A report of three cases treated with intravenous gammaglobulin // Rev. Alerg. Mex. 2006 Sep-Oct; 53(5): 183-8.

Vyhnаnek F., Kostka R., Lochmann O. Immunotherapy as part of comprehensive therapy in abdominal reoperations with septic complications // Acta Medica (Hradec Kralove) Suppl. 1997; 40(2): 97-100.

Weisman L.E., Stoll B.J., Kueser T.J. et al. Intravenous immune globulin therapy for early-onset sepsis in premature neonates // J. Pediatr. 1992 Sep; 121(3): 434-43.

Werdan K., Pilz G., Bujdoso O. et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study // Crit. Care Med. 2007 Dec; 35(12): 2693-2701.

Wesoly C., Kipping N., Grundmann R. Immunoglobulin therapy of postoperative sepsis // Z. Exp. Chir. Transplant. Kunstliche Organe. 1990; 23(4): 213-6.

Wynes J., Harris W. 4th, Hadfield R.A., Malay D.S. Subtalar joint septic arthritis in a patient with hypogammaglobulinemia // J. Foot Ankle Surg. 2013 Mar-Apr; 52(2): 242-8.

Octagam Data on File.

Octagam 5 % Summary of Product Characteristics.




DOI: https://doi.org/10.22141/2224-0586.1.64.2015.79543

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru